Plasma metformin concentration as a determinant of metabolic response in adults with type 1 diabetes: a 1-year prospective observational study
Abstract
Background: Metformin is commonly used as adjunctive therapy in adults with type 1 diabetes (T1DM), although evidence regarding its long-term metabolic effects remains inconsistent. To assess the metabolic effects of adjunctive metformin therapy in adults with type 1 diabetes (T1DM) over a 12-month period, using advanced markers of metabolic control, including time in range (TIR), estimated glucose disposal rate (eGDR), and monitoring of metformin plasma concentrations.
Methods: This single-center, observational study included 26 adults with T1DM treated with extended-release metformin (500-2000 mg/day). Metformin plasma concentrations were measured at baseline and at 5 time points up to 12 months using a validated UPLC-MS/MS method. Glycemic control (TIR), insulin dose, anthropometric parameters, lipid profile, visceral adiposity index (VAI), and eGDR were assessed. Participants were grouped by median metformin concentration.
Results: Interindividual variability in metformin plasma concentrations was significant. Adjunctive metformin therapy was associated with significant reductions in LDL cholesterol, non-HDL cholesterol, and VAI. A significant transient improvement in eGDR was observed after 6 months of therapy, followed by partial attenuation at 12 months. A significant interaction between metformin concentration subgroup and time was observed for TIR (p = 0.0151), with descriptively greater improvement in participants with higher metformin concentrations. No…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.